The partnership combines Sciwind's expertise in disease
biology and clinical development capabilities with SynerK's
proprietary conjugate-based siRNA delivery technology and expertise
in developing RNAi therapeutics
SAN
FRANCISCO, Calif. and HANGZHOU,
China, Sept. 26, 2022 /PRNewswire/
-- Sciwind Biosciences, a clinical-stage biopharmaceutical
company focused on discovering and developing innovative therapies
to treat metabolic disease,and SynerK, a leading RNAi
therapeutics discovery and development company, announced today
that they have entered into a research partnership to jointly
discover and develop new therapeutics based on small interfering
RNA (siRNA) technology to treat liver and metabolic diseases
marked by unmet medical needs.
This partnership will bring together the expertise of the two
companies in the discovery and development of innovative therapies
against important human diseases. Through this collaboration, the
two companies will work together to identify new therapeutic
targets that play critical roles in disease biology for a broad
range of liver and metabolic diseases and to discover and develop
novel siRNA therapeutics against these targets.
"We are very pleased to have the opportunity to work with the
SynerK team and utilize SynerK's proprietary siRNA technology
platform to discover new therapies to treat chronic diseases for
which effective treatments are still urgently needed," said Dr.
Weidong Zhong, President of Sciwind
Biosciences. "This research partnership will provide exciting
opportunities for both companies to explore new disease targets or
targets that have not been successfully modulated through
conventional therapeutic modalities, such as protein or small
molecule drugs."
"We are excited to enter into this collaborative research
agreement with Sciwind, an industry leader in the discovery and
development of innovative therapies for metabolic disease.
Sciwind's deep insight and knowledge in disease biology is
invaluable for this collaboration as we develop new RNA-based
therapeutics to treat diseases that were previously untreatable.
SynerK was founded by a team of industry veterans with deep
expertise in oligonucleotide-based technology and broad experience
across all phases of siRNA therapeutics development. The team
has developed a proprietary delivery technology platform
demonstrating high delivery efficiency to targeted human cells and
a good safety profile both in vitro and in
vivo. Using this platform, SynerK has advanced multiple
siRNA-based drug candidates with first-in-class or best-in-class
potential into preclinical development," said Dr. Wayne Jiang, co-founder of SynerK. "By
utilizing our proprietary siRNA technology platforms, we will
work with Sciwind team to explore new opportunities to discover
siRNA therapeutics to help patients with unmet medical needs."
About Sciwind
Sciwind Biosciences is a clinical stage biopharmaceutical
company focusing on discovering and developing innovative therapies
to treat metabolic disease. Its product pipeline consists of
potentially first-in-class and best-in-class drug candidates.
Sciwind has developed multiple proprietary technologies, including
oral peptide and inhaled protein therapeutic delivery platforms and
identified a series of drug candidates based on these core platform
technologies. For more information, visit
www.sciwindbio.com.
About SynerK
SynerK Inc. is a biopharmaceutical company focused on developing
RNA-targeted therapeutics. SynerK has three R&D centers located
in Boston, USA, Suzhou and Beijing, China. SynerK's founders are seasoned
industry experts in the discovery and development of RNA
therapeutics. SynerK aims to build a world-class RNA-target
therapeutics company and treat diseases that have previously been
difficult or impossible to treat through traditional
approaches. For more information, visit www.synerk.com.
View original
content:https://www.prnewswire.com/news-releases/sciwind-biosciences-and-synerk-enter-into-research-partnership-to-discover-and-develop-novel-sirna-therapeutics-301632849.html
SOURCE Hangzhou Sciwind Biosciences Co., Ltd.